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ReportsSafety of rAAV2/2-ND4 Gene
Therapy for Leber Hereditary
Optic NeuropathyLeber hereditary optic neuropathy (LHON) is the most commonly
recognized mitochondrial disease. It typically occurs in young male
adults, causing painless, acute, and profound vision loss. It presents
asynchronously with the second eye almost always involved within
weeks or months, a phenotypic declaration nearly pathognomonic
for LHON. Visual prognosis is poor and therapy wanting.1
Leber hereditary optic neuropathy is caused by mutations in
mitochondrial genes encoding proteins of the respiratory chain
complex I. Approximately 70% of subjects with LHON carry the
point mutation G11778A in the ND4 gene encoding NADH
dehydrogenase protein subunit 4 (ND4), accounting for the most
severe phenotype.2 Retinal ganglion cells are primarily affected by
this mitochondrial dysfunction, leading to apoptotic cell death and
ensuing optic nerve atrophy.1
Our therapy is based on a technology that demonstrably rescued
an induced defect in respiratory chain complex I in rat retinas andTable 1. Ocular Treatment-Emergent Adverse Events and Outcom
rAA
9  109 vg/eye
(n ¼ 3)
3  1010 vg/e
(n ¼ 3)
All Ocular TEAEs 4/3 10/3
Anterior chamber inﬂammation 0 2/2
Subconjunctival hemorrhage 0 0
Allergic conjunctivitis 1/1 0
Punctate serous detachment 0 0
Eye pain 0 1/1
Keratitis 0 1/1
Ocular hypertension 2/2 3/3
Vitreous hemorrhage 0 0
Vitritis 1/1 3/2
Positive Seidel test 0 0
Cataract extraction (elective) 1/1 0










TEAE ¼ treatment-emergent adverse event; VG ¼ vector genomes.
Results are presented as N events/N subjects.
*Includes subjects of cohorts 3 and 5.
yTwo events were considered unrelated to rAAV2/2-ND4 or the procedure; th
rAAV2/2-ND4.
zAll events were considered to be probably related to the procedure.
xOf 10 events, 6 were considered to be related to rAAV2/2-ND4, and 4 were
kSubject withdrew consent after week 48.
#All events were considered to be probably related to rAAV2/2-ND4.prevented retinal ganglion cell degeneration.3 rAAV2/2-ND4
(GS010) is a recombinant, replication-defective, adeno-associated
virus, serotype 2, containing a modiﬁed cDNA encoding the
human wild-type mitochondrial ND4 protein and supporting its
allotopic expression,3 that is, the expression of a mitochondrial
gene by the nucleus and subsequent co-translation and importa-
tion of the wild-type protein into the mitochondrial matrix. rAAV2/
2-ND4 was investigated in an open-label single-center Phase I/II
clinical trial that included 4 dose-escalation cohorts (9  109 vector
genomes [vg]/eye, 3  1010 vg/eye, 9  1010 vg/eye, 1.8  1011
vg/eye) and an extension cohort (9  1010 vg/eye). Fifteen subjects
with LHON carrying the ND4-G11778A mutation were prospec-
tively enrolled. Each subject received a single intravitreal injection
of rAAV2/2-ND4 in the worse-seeing eye. The study design
included an initial follow-up period of 48 weeks, followed by
longer-term follow-up for an additional 4 years. The primary
objective was the safety and tolerability of escalating doses of
rAAV2/2-ND4. Secondary objectives included bio-dissemination
and immunogenicity of rAAV2/2-ND4 and evaluation of visual
functions. The study received approval of the French Ethicses of the Most Common Treatment-Emergent Adverse Events
V2/2-ND4 doses
All (N [ 15)
ye 9  1010 vg/eye
(n ¼ 6)*




















e remaining 12 events were considered to be probably related to
related to the procedure.
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Ophthalmology Volume 125, Number 6, June 2018Committee and adhered to the tenets of the Declaration of Helsinki;
it was registered on Clinicaltrial.gov (NCT02064569).
Subjects were mostly male (n ¼ 13) with an average age of 47
years. Vision loss durationwas heterogeneous, ranging from8 to 271
months at enrollment (Table S1, available at www.aaojournal.org).
The incidence, type, severity, and presumed causality of treatment-
emergent adverse events (TEAEs) were collected for each subject
at all study visits. Each event was recorded as a separate adverse
event even when occurring simultaneously (e.g., anterior and vitre-
ous inﬂammation). Visual parameters measured included best-
corrected visual acuity (BCVA), Pelli-Robson contrast sensitivity,
15-hue color vision, Humphrey Visual Field 24-2, Octopus peri-
metry, microperimetry, visual evoked potentials, and pattern
electroretinogram.
At week 96, 96 TEAEs were reported involving all 15 subjects,
including 40 systemic TEAEs and 56 ocular TEAEs, consistent
with previous studies using intravitreal injections (Table 1).4,5
There were no unexpected TEAEs, no serious adverse events
related to the treatment or procedure, and no suspected unexpected
serious adverse reactions. No deaths and no TEAEs leading to
study discontinuation were reported. Ninety of the 96 TEAEs
(94%) were mild in intensity. Of the 56 ocular TEAEs, 2 events
occurred in 1 untreated eye and 2 were elective cataract extraction.
Thirty-four (61%) and 18 (32%) TEAEs were considered treatment
and procedure related, respectively. Fifty-one ocular TEAEs (91%)
were mild. One moderate event of intraocular pressure (IOP)
elevation (34 mmHg) occurred in the only subject who did not
receive a pretreatment IOP-lowering agent. Another subject
concomitantly experienced an event of ocular pain and moderate
elevation of IOP (38 mmHg), followed by 2 severe events: anterior
chamber inﬂammation and vitritis.
The most frequent ocular TEAEs were intraocular inﬂammation
and IOP elevation. Twenty-seven events of intraocular inﬂamma-
tion were reported in 13 subjects, starting from 7 to 541 days
posttreatment. All were mild, except 2 severe events that occurred
in a single subject. All were deemed probably related to treatment,
except for 2 TEAEs that occurred in 1 untreated eye (subject had a
history of idiopathic uveitis). Most affected subjects were treated
for their ocular inﬂammation with topical anti-inﬂammatory
agents. Two subjects were given oral steroids: the subject with
severe intraocular inﬂammation and another subject with mild
vitritis.
Ten events of IOP elevation following intravitreal injection
were reported in 9 subjects, starting 4 hours to 30 days after in-
jection. Most cases were mild, except for 2 subjects with moderate
IOP elevation. Day-of-treatment IOP elevation was deemed to be
procedure related (due to the injection). Delayed IOP elevation was
deemed treatment related, and such subjects developed subsequent
intraocular inﬂammation, precipitating steroid use.
All ocular events resolved spontaneously or after appropriate
therapy with IOP-lowering or anti-inﬂammatory therapy, except
for 1 subject with ongoing mild vitritis (0.5þ vitreous cell, no
vitreous haze, no treatment required at last visit), subsequently lost
to follow-up but without documented worsening of TEAE. At
week 96, no related TEAEs required ongoing treatment. No
anatomic sequelae were documented by fundus examination or
spectral domain OCT, and no vision loss was reported due to
treatment or TEAEs. A total of 40 systemic TEAEs were reported
over 96 weeks; none were related to rAAV2/2-ND4 or the study
procedures (Table S2, available at www.aaojournal.org).946Although this study was neither designed nor powered to
ascertain efﬁcacy, a clinically signiﬁcant improvement in BCVA
was noted in the treated eyes of 6 of 14 subjects at week 96 (similar
proportions at week 48 and week 78). A between-eye difference in
visual acuity change from baseline favoring the treated eye was
observed at week 96 in the subset of subjects with disease duration
2 years and BCVA 20/12000 at inclusion (0.278 logarithm of
the minimum angle of resolution [logMAR] [þ14 Early Treatment
Diabetic Retinopathy Study {ETDRS} letters] 95% conﬁdence
interval [CI], 0.853 to þ0.297). This between-eye difference was
also observed at week 48 and week 78 (0.338 logMAR [þ17
ETDRS letters] 95% CI, 0.856 to þ0.180 and 0.398 logMAR
[þ20 ETDRS letters] 95% CI, 1.021 to þ0.225, respectively).
Our study demonstrates that rAAV2/2-ND4 is safe and well
tolerated 2 years after a single unilateral intravitreal administration.
Our 2 ongoing Phase III clinical studies in similar subjects,
RESCUE (vision loss duration of 6 months) and REVERSE
(vision loss duration of >6 months to 1 year), should help reﬁne
and inform the trends of improvement in visual outcome that we
have reported and further validate the safety and tolerability of
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34-Gauge Needle for
Intravitreal InjectionsIntravitreal injections of antievascular endothelial growth factor
agents have achieved excellent results1,2 and have become one of
the most frequently performed intraocular procedures. Although
intravitreal drug delivery of antievascular endothelial growth
factor agents is effective, patients often report discomfort during
the procedure. A literature review in a previous study of the use of
a 33-gauge needle for intravitreal injections3 indicated that there is
no consensus regarding the effect of the intravitreal needle size and
perceived pain. Therefore, we conducted the current study to
evaluate the effectiveness of the short 34-gauge needle on patient
perceptions of pain during intravitreal injections.We performed a prospective, randomized, double-armed,
single-blinded clinical trial to evaluate the usefulness of the short
34-gauge needle for intravitreal injections compared with the
30-gauge needle. This study was conducted according to the tenets
of the Declaration of Helsinki; the Aichi Medical University
Hospital institutional review board approved the study, which is
registered at the University Hospital Medical Information Network
Clinical Trial site (http://www.umin.ac.jp/ctr/index-j.htm;
UMIN000024903). After providing written informed consent, all
patients underwent ophthalmic examinations, including slit-lamp
and fundus examinations and intraocular pressure (IOP; Tonoref
II [Nidek Co., Ltd., Aichi, Japan]) and axial length (AL-Scan,
Nidek Co., Ltd.) measurements.
Patients were assigned randomly to an intravitreal injection either
using a 30-gauge needle (0.3 19 mm; Nipro, Inc., Osaka, Japan) or a
34-gauge needle (0.18  8 mm; Pasny [Nanbu Plastics Co., Ltd., Shi-
zuoka, Japan]; Fig S1, available at www.aaojournal.org). Either
ranibizumab (Lucentis; Genentech, South San Francisco, CA) 0.05 ml
(0.5 mg) or aﬂibercept (Eylea; Regeneron Pharmaceuticals, Inc.,
Tarrytown, NY) 0.05 ml (2 mg) was administered. We used a preﬁlled
syringe for ranibizumab and a 1-ml syringe for aﬂibercept; these were
attached to either a 30- or 34-gauge needle. Two surgeons (H.S. and
H.O.) administered intravitreal injections in our outpatient ofﬁce.
All eyes were anesthetized with a 2% lidocaine (Xylocaine;
Aspen Japan K.K., Tokyo, Japan) eye drop and were sterilized with
5% povidone iodine eye drops.4 A sterile lid speculum was
inserted, and all injections were performed at a straight angle via
the pars plana 3.5 to 4.0 mm posterior to the limbus in the upper
temporal or nasal quadrant. Immediately after injections, the
surgeons checked the hand movement visual acuity. The IOP
was measured while the patients were sitting before, immediately
after, and 20 minutes after the injection using an Icare PRO
tonometer (Tiolat Oy, Helsinki, Finland). If patients reported
visual loss or the IOP became too elevated, a paracentesis was
considered to prevent central retinal artery occlusion.
A research nurse asked the patients to rate their pain using a
numeric rating scale ranging from 0 to 10,5 in which 0 indicated no
pain and 10 indicated the most intense pain immediately after the
injection. The average of these scores was the primary outcome.
The surgeons assessed the puncture resistance, reﬂux after injection,
subconjunctival hemorrhage, and ocular movements during the
intravitreal injections on a 0 (undetectable) to 1 (detectable) scale.
Statistical analyses were performed using the SAS System soft-
ware version 9.4 (SAS Institute, Cary, NC). A statistician (K.M.)
performed all analyses and was blinded to the group assignments.
TheManneWhitneyU test was used to analyze continuous variables
and the Fisher exact test was used for categorical variables.
One hundred forty eyes of 110 consecutive patients were
enrolled. The baseline characteristics did not differ signiﬁcantly
between the groups (Table S1, available at www.aaojournal.org).
The short 34-gauge needle was associated with a signiﬁcantly
(P < 0.0001) lower pain score than the 30-gauge needle (median
interquartile range [IQR], 2 [3] vs. 4 [4], respectively; mean 
standard deviation, 1.91.64 vs. 42.53, respectively; Fig 2).
The puncture resistance (0 vs. 45 times, respectively) and reﬂux
after injection (1 vs. 22 times, respectively) were signiﬁcantly
(P < 0.0001 for both comparisons) lower with the 34-gauge nee-
dle; the subconjunctival hemorrhage (10 vs. 15 times, respectively;
P ¼ 0.27) and ocular movement (3 vs. 7 times, respectively;
P ¼ 0.20) scores did not differ signiﬁcantly between the groups.947
